Hamps Bio Ltd's shares made a stellar debut on the BSE SME platform on December 20, 2024, listing at Rs 96.9, a 90 per cent premium over its issue price of Rs 51. The Initial Public Offering (IPO), entirely a fresh equity sale, received an overwhelming response and was oversubscribed by 1000 times.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Utilization of IPO proceeds
Hamps Bio aims to utilise the Rs 10.71 crore raised through its IPO to purchase machinery for its FMCG division, strengthen brand visibility, and perform other corporate purposes.

Expanding product portfolio and market presence
Hamps Bio is a recognized player in ethical pharmaceutical marketing and manufacturing. Its portfolio includes over 180 pharmaceutical formulations like tablets, syrups, capsules, injectables, and nutraceutical products, as well as freeze-dried and frozen food products under its brand 'FzyEzy.' The company’s pharma products are distributed across eight Indian states and union territories, while its FDFP products are exported to six countries.

Financial snapshot
For the period ending October 2024, the company reported a total revenue of Rs 4.36 crore and a net profit of Rs 34 lakh.

India’s key role in global pharma
Hamps Bio’s growth is aligned with India's pivotal role in the global pharmaceutical landscape. The country contributes 20 per cent to the global supply of generic medicines and 60 per cent to the vaccine supply, highlighting strong opportunities for domestic players like Hamps Bio.

With its robust debut, Hamps Bio underscores investor confidence in India’s growing SME segment, particularly in pharmaceuticals and FMCG, showcasing its potential for long-term growth.